Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support company's transformation and growth in autoimmune disease CAMBRIDGE, Mass., July ...

Pfizer faces adjusted financial forecasts as analysts lower earnings expectations for FY2025, signaling cautious optimism.

In a report released yesterday, Carter Gould from Cantor Fitzgerald maintained a Hold rating on Merck & Company, with a price target of $83.00. The company’s shares closed yesterday at $83.71.

US regulators approved Moderna Inc.’s COVID-19 vaccine for children, but for a narrower group than before, continuing Robert ...

Stock indexes closed higher on Wall Street, enough to nudge the S&P 500 and the Nasdaq composite to more records. The S&P 500 ...

U.S. stock indexes are mixed as Wall Street sizes up a batch of corporate quarterly results. Delta Air Lines led a rally in airline stocks after releasing a solid outlook ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...

With a market cap of $145.7 billion, Pfizer Inc. (PFE) is a global, research-driven biopharmaceutical company, specializing ...

Pfizer has boldly stepped into the burgeoning cannabis light market, giving the industry a serious growth spurt. The Cannabis ...

"We're going to be announcing pharmaceuticals, chips and various couple of other things - you know, big ones," Trump told ...

Pfizer Inc. closed 18.77% short of its 52-week high of $31.54, which the company achieved on July 30th.